The association of vitamin D receptor gene polymorphisms and serum 25-hydroxyvitamin D levels with generalized vitiligo

British Journal of Dermatology

Volumn 167, Issue 4, 2012, Pages 815-821

  Li, K ^a   Shi, Q ^a   Yang, L ^a   Li, X ^a   Liu, L ^a   Wang, L ^a   Li, Q ^a   Wang, G ^a   Li, C Y ^a   Gao, T W ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; VITAMIN D RECEPTOR;

ADULT; ALLELE; ARTICLE; CHINESE; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VITILIGO;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHILD; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; POLYMORPHISM, GENETIC; RECEPTORS, CALCITRIOL; VITAMIN D; VITILIGO; YOUNG ADULT;

EID: 84867017443     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11132.x     Document Type: Article

References (35)

1. Alkhateeb A, Fain PR, Thody A, et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 2003; 16: 208-14.
2. Lu T, Gao T, Wang A, et al. Vitiligo prevalence study in Shaanxi Province, China. Int J Dermatol 2007; 46: 47-51.
3. Le Poole C, Boissy RE,. Vitiligo. Semin Cutan Med Surg 1997; 16: 3-14.
4. Passeron T, Ortonne JP,. Physiopathology and genetics of vitiligo. J Autoimmun 2005; 25 (Suppl.): 63-8.
5. Le Poole IC, Wankowicz-Kalinska A, van den Wijngaard RM, et al. Autoimmune aspects of depigmentation in vitiligo. J Investig Dermatol Symp Proc 2004; 9: 68-72.
6. Ongenae K, Van Geel N, Naeyaert JM,. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16: 90-100.
7. Niepomniszcze H, Amad RH,. Skin disorders and thyroid diseases. J Endocrinol Invest 2001; 24: 628-38.
8. Weiss GR, Fehrenkamp SH, Tokaz LK, et al. Vitiligo and Graves' disease following treatment of malignant melanoma with recombinant human interleukin 4. Dermatology 1996; 192: 283-5.
9. Adorini L, Penna G,. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 2008; 4: 404-12.
10. Amano H, Abe M, Ishikawa O,. First case report of topical tacalcitol for vitiligo repigmentation. Pediatr Dermatol 2008; 25: 262-4.
11. Parsad D, Kanwar AJ,. Topical vitamin D analogues in the treatment of vitiligo. Pigment Cell Melanoma Res 2009; 22: 487-8.
12. Ersoy-Evans S,. Commentary: vitamin D and autoimmunity: is there an association? J Am Acad Dermatol 2010; 62: 942-4.
13. Mora JR, Iwata M, von Andrian UH,. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol 2008; 8: 685-98.
14. Uitterlinden AG, Fang Y, Van Meurs JB, et al. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004; 338: 143-56.
15. Haussler MR, Whitfield GK, Haussler CA, et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998; 13: 325-49.
16. Morrison NA, Qi JC, Tokita A, et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994; 367: 284-7.
17. Ozaki Y, Nomura S, Nagahama M, et al. Vitamin-D receptor genotype and renal disorder in Japanese patients with systemic lupus erythematosus. Nephron 2000; 85: 86-91.
18. Maalej A, Petit-Teixeira E, Michou L, et al. Association study of VDR gene with rheumatoid arthritis in the French population. Genes Immun 2005; 6: 707-11.
19. Zemunik T, Skrabic V, Boraska V, et al. FokI polymorphism, vitamin D receptor, and interleukin-1 receptor haplotypes are associated with type 1 diabetes in the Dalmatian population. J Mol Diagn 2005; 7: 600-4.
20. Bentley RW, Keown D, Merriman TR, et al. Vitamin D receptor gene polymorphism associated with inflammatory bowel disease in New Zealand males. Aliment Pharmacol Ther 2011; 33: 855-6.
21. Mee JB, Cork MJ,. Vitamin D receptor polymorphism and calcipotriol response in patients with psoriasis. J Invest Dermatol 1998; 110: 301-2.
22. Birlea S, Birlea M, Cimponeriu D, et al. Autoimmune diseases and vitamin D receptor Apa-I polymorphism are associated with vitiligo in a small inbred Romanian community. Acta Derm Venereol 2006; 86: 209-14.
23. Silverberg JI, Silverberg AI, Malka E, et al. A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. J Am Acad Dermatol 2010; 62: 937-41.
24. Liu L, Li C, Gao J, et al. Promoter variant in the catalase gene is associated with vitiligo in Chinese people. J Invest Dermatol 2010; 130: 2647-53.
25. Monticielo OA, Brenol JC, Chies JA, et al. The role of BsmI and FokI vitamin D receptor gene polymorphisms and serum 25-hydroxyvitamin D in Brazilian patients with systemic lupus erythematosus. Lupus 2012; 21: 43-52.
26. Vogel A, Strassburg CP, Manns MP,. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 2002; 35: 126-31.
27. Park BS, Park JS, Lee DY, et al. Vitamin D receptor polymorphism is associated with psoriasis. J Invest Dermatol 1999; 112: 113-16.
28. Valdivielso JM, Fernandez E,. Vitamin D receptor polymorphisms and diseases. Clin Chim Acta 2006; 371: 1-12.
29. Smolders J, Damoiseaux J, Menheere P, et al. Fok-I vitamin D receptor gene polymorphism (rs10735810) and vitamin D metabolism in multiple sclerosis. J Neuroimmunol 2009; 207: 117-21.
30. Penna G, Adorini L,. 1-Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164: 2405-11.
31. D'Ambrosio D, Cippitelli M, Cocciolo MG, et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest 1998; 101: 252-62.
32. Cippitelli M, Santoni A,. Vitamin D3: a transcriptional modulator of the interferon-gamma gene. Eur J Immunol 1998; 28: 3017-30.
33. Takeuchi A, Reddy GS, Kobayashi T, et al. Nuclear factor of activated T cells (NFAT) as a molecular target for 1alpha,25-dihydroxyvitamin D3-mediated effects. J Immunol 1998; 160: 209-18.
34. Loser K, Mehling A, Loeser S, et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 2006; 12: 1372-9.
35. Spach KM, Nashold FE, Dittel BN, et al. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol 2006; 177: 6030-7.